HomepageANW ā¢ FRA
add
Immuron Ltd
Vorige slotkoers
ā¬Ā 0,034
Dag-range
ā¬Ā 0,036 - ā¬Ā 0,036
Jaar-range
ā¬Ā 0,027 - ā¬Ā 0,067
Beurswaarde
17,97Ā mln. AUD
Koers/winst
-
Dividendrendement
-
Primaire beurs
ASX
Marktnieuws
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(AUD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 2,00Ā mln. | 69,57% |
Bedrijfskosten | 2,60Ā mln. | 44,31% |
Netto inkomsten | -1,24Ā mln. | -20,05% |
Netto winstmarge | -62,31 | 29,20% |
Winst per aandeel | ā | ā |
EBITDA | -1,27Ā mln. | -25,76% |
Effectief belastingtarief | ā | ā |
Balans
Totale activa
Totale passiva
(AUD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 7,74Ā mln. | -52,88% |
Totale activa | 12,17Ā mln. | -38,79% |
Totale passiva | 1,83Ā mln. | -22,32% |
Totaal aandelenvermogen | 10,34Ā mln. | ā |
Uitstaande aandelen | 229,15Ā mln. | ā |
Koers-boekwaardeverhouding | 0,67 | ā |
Rendement op activa | -26,08% | ā |
Rendement op kapitaal | -30,30% | ā |
Kasstroom
Nettomutatie in liquide middelen
(AUD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -1,24Ā mln. | -20,05% |
Operationele kasstroom | -2,00Ā mln. | -99,29% |
Kasstroom uit beleggingen | 27,00K | -64,83% |
Kasstroom uit financiering | -20,95K | -80,85% |
Nettomutatie in liquide middelen | -1,96Ā mln. | -101,45% |
Vrije kasstroom | -794,63K | -25,63% |
Over
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Opgericht
1994
Hoofdvestiging
Website
Werknemers
7